作者： sarah

TOKYO & JAKARTA, Dec 6, 2024 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., and PT. JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (collectively referred to as "JCB"), have entered into an exclusive sponsorship agreement with PT Senayan Trikarya Sempana (STS) for Yashinoki Yokocho, a Japanese food court and Japanese travel information center set to open in Plaza Senayan, the luxury shopping mall in Indonesia.Prior to the soft opening on December 20, 2024, on December 6, 2024, JCB hosted the Japan Event in collaboration with Japanese restaurants that will open in Yashinoki Yokocho, local governments and Japanese commercial establishments that aim to attract inbound tourists, and multiple Japanese companies operating in Indonesia. The event invited famous Indonesian Key Opinion Leaders (KOLs) to discuss Japanese content and the appeal of traveling to Japan, deepening the understanding of the importance of Yashinoki Yokocho in providing a Japan experience while staying in Indonesia.JCB's Initiatives at Yashinoki YokochoYashinoki Yokocho, located in Plaza Senayan, will feature 14 stores, including Japanese restaurants opening their first location in Indonesia and a JCB SUGOI JAPAN booth, allowing visitors to experience an authentic Japanese atmosphere and enjoy real Japanese cuisine in Indonesia. The JCB SUGOI JAPAN booth will serve as an information center for travel to Japan and will also provide an opportunity for those interested to apply on the spot for JCB Cards with travel benefits in Japan.As the sole sponsor of Yashinoki Yokocho, JCB will develop various programs for JCB cardmembers in Yashinoki Yokocho, including:1. Sharing Information to promote travel to Japan2. Promotions with benefits and raffle for trip to Japan based on card usage3. Japan-related eventsJCB aims to further appeal to Indonesia's Japan enthusiasts by showcasing the unique charm of Japan.Background of SponsorshipIn recent years, Indonesia has experienced remarkable economic growth, with a particularly notable expansion of its affluent class. Many of these affluent customers have a strong interest in Japan, prompting JCB to focus on providing unique Japanese value under the slogan "SUGOI JAPAN". With the growth of the Japanese inbound market, JCB has been offering comprehensive services through partnerships with Japanese companies in both Indonesia and Japan.This sponsorship was accomplished through the aligned visions of STS to enhance services for visitors to Plaza Senayan and JCB to deliver its distinctive value to Indonesian customers. JCB will continue to expand its unique Japanese value and strive to become a leading payment brand.Concept of SUGOI JAPANJCB has been developing unique services with the slogan "SUGOI JAPAN", including 3 categories "VISIT JAPAN", "JCB DAY", and "JAPAN DINING".About Plaza Senayan and STSOperating since 1996, Plaza Senayan is a luxury mall in Jakarta featuring over 200 tenants, including luxury brands, restaurants, and cafes. It has consistently met the diverse needs of Indonesian customers. Plaza Senayan is operated by STS, established as a subsidiary of Kajima Corporation in 1990, as a core facility of the large-scale Senayan Square complex developed on approximately 190,000 square meters of state-owned land leased by Kajima Corporation, the parent company of STS. https://plaza-senayan.com/ About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 49 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 158 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO & JAKARTA, Dec 6, 2024 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd., has signed a Memorandum of Understanding with the Kobe Tourism Bureau to promote inbound tourism. This partnership will strengthen the response to inbound demand mainly from affluent customers, primarily in the rapidly growing Indonesian market as a trial.Partnership OverviewBased on this memorandum, JCB and the Kobe Tourism Bureau will develop comprehensive tourism promotion strategies.Specifically, JCB and the Kobe Tourism Bureau will begin marketing trial initiatives aimed at stimulating consumption in Kobe with JCB Cards issued in Indonesia in January 2025. The partnership will offer special benefit programs at luxury hotels and traditional Japanese restaurants in Kobe, and it will gradually introduce exclusive benefits for JCB cardmembers at famous tourist spots in Kobe. Through these efforts, JCB and the Kobe Tourism Bureau aim to create added value for Japanese enthusiasts in Indonesia and improve their satisfaction during their stay in Kobe.In addition, the partnership will conduct behavioral analysis of inbound tourists using statistical data* on the consumption patterns of JCB cardmembers. Based on this information, JCB and the Kobe Tourism Bureau will effectively promote Kobe's attractions to Indonesian JCB cardmembers and work to build a model that strengthens the response to inbound demand through collaboration between the local government and the private sector.*Statistical data includes information on JCB Cards issued in Indonesia and other overseas markets, including card usage areas, industries and the amount of card transactions made in Kobe City.Background of the MemorandumIn recent years, Indonesia has seen remarkable economic development with a rapidly growing affluent class and increasing interest in high-quality tourism to Japan. JCB has been developing unique services with the slogan "SUGOI JAPAN", including 3 categories "VISIT JAPAN", "JCB DAY", and "JAPAN DINING".This partnership will further develop these initiatives by combining the Kobe Tourism Bureau's tourism promotion strategies with JCB's payment platform. JCB will work closely with the Kobe Tourism Bureau to enhance convenience and stimulate consumption by tourists from Indonesia. By maximizing the knowledge and networks of both parties, JCB and the Kobe Tourism Bureau will contribute to Kobe's tourism promotion and sustainable economic development. In addition, JCB aims to become a leading payment brand by developing unique Japanese value propositions with the slogan "SUGOI JAPAN".About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 49 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 158 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., Dec 5, 2024 - (JCN Newswire via SeaPRwire.com) -  Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (AD)*.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils**), as well as insoluble Aβ aggregates (fibrils) which are amajor component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates, and Great Britain.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study,LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2)Approximately 1.3 million people in Mexico are estimated to suffer from AD, accounting for 60-70% of all dementia diagnoses.3 AD most commonly affects individuals over the age of 65.(3)Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai and Biogen will co-commercialize and co-promote LEQEMBI in Mexico.*Collectively referred to mild cognitive impairment due to AD or mild AD dementia.**Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(4) Protofibrils cause injury toneurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(5)About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulingamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab is approved and being marketed in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) ormild dementia stage of disease (collectively referred to as early AD). The treatment’s approvals in these countries was based onPhase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The most common adverse events (>10%) in the lecanemab group were infusion reactions,ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.Lecanemab is under regulatory review in 16 countries and regions, including the European Union. In November 2024, thetreatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normaland have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti- amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisaiserves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializingand co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&Dfacilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseaseswith high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S.headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters:Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com.Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof;the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, andonly a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in suchstatements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficultto complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse toapprove or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and otherproprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and thirdparty collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factorsthat could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in otherreports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.References(1) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: www.eisai.com/news/2022/news202285.html(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. www.nejm.org/doi/full/10.1056/NEJMoa2212948(3) Secretaría de Salud. Enfermedad de Alzheimer, demencia más común que afecta a personas adultas mayores. Oct 2021. https://tinyurl.com/ttv486xx(4) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(5) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.MEDIA CONTACTSEisai Co., Ltd.Public Relations Department TEL : +81 (0)3-3817-5120INVESTOR CONTACTSEisai Co., Ltd.Investor Relations Department TEL: +81 (0) 3-3817-5122Biogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comBiogen Inc.Stephen Amato+ 1-781-464-2442IR@biogen.com Copyright 2024 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, Dec 4, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO Corporation has recently signed a Memorandum of Understanding (MOU) with Canatu to advance the practical application of carbon nanotube technology. By strengthening their partnership, the two companies aim to deepen their collaboration to contribute to the advancement of autonomous driving technology and the realization of carbon neutrality.As autonomous driving technology continues to evolve, vehicles must accurately detect their surroundings using cameras and other sensors. However, issues such as frost and condensation can obstruct visibility and complicate detection. To address these challenges, DENSO is developing products that utilize transparent conductive films made from flexible, transparent materials. Carbon nanotube technology is key to these developments.Carbon nanotubes are carbon-based materials with extremely fine structures, characterized by high strength, light weight, and excellent electrical and thermal conductivity. They hold great promise for a wide range of applications. Canatu has innovative technology that enables the efficient production of high-purity carbon nanotubes using proprietary materials and has strengths in transparent conductive film formation.DENSO has been collaborating with Canatu by combining Canatu’s advanced transparent conductive film technology with DENSO’s expertise in automotive technology and mass production. In April this year, the companies successfully developed a reactor* at Canatu’s production facility in Finland, significantly enhancing the productivity of carbon nanotubes. They have also been jointly developing transparent heaters for vehicle cameras and windshields. Moving forward, DENSO and Canatu will continue to drive efforts toward the commercialization of transparent heaters while also expand their application to environmental technologies. Their goal is to establish technologies that contribute to carbon neutrality.Key Areas of CollaborationDENSO and Canatu will accelerate initiatives in the following three areas to achieve practical applications of carbon nanotube technology:1. Research and DevelopmentDevelop new applications, including transparent heaters and solar power technologies, utilizing carbon nanotubes.2. Mass Production TechnologiesCollaborate on improving manufacturing equipment and processes to achieve the quality required for mass production.3. Global Supply Chain DevelopmentBegin exploring the establishment of a reliable supply system to ensure the stable and consistent delivery of high-quality products.DENSO will continue advancing technology development in collaboration with partners across various fields, contributing to sustainable mobility for people and the planet.*Reactor: Equipment used for manufacturing carbon nanotubes. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Dec 3, 2024 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. and its rugby team, MIE Honda HEAT, today held a rally event at the Aoyama Welcome Plaza in the Honda Global Head Office in Tokyo, ahead of the NTT Japan Rugby League One 2024-2025 season, which begins on Saturday, December 21, 2024.At the event, Manabu Ozawa, a Managing Executive Officer of Honda concurrently serving as Executive Advisor of MIE Honda HEAT, introduced the Honda vision for its sports activities – to increase the number of people who take on challenges through sports activities and make the lives of all people more enjoyable. He also announced the MIE Honda HEAT team value – “BIND” All Dreams – which was newly established in the pursuit of the team’s vision to become “the strongest, most respected, most loved” team. The “team value” represents the team’s desire to “take on challenges and chase dreams together with all people involved with MIE Honda HEAT.”Other key staff members and players on the team who expressed their strong passion and commitment for the upcoming season included Head Coach Kieran Crowley, General Manager Yoshihito Maeda, the new captain Takumi Fujii, and other key players, including Lemeki Lomano Lava, who returned to the team for the first time in four years. The MIE Honda HEAT was founded in 1961, as the Honda rugby team based in the City of Suzuka, in Mie Prefecture, Japan. Since last season (2023-2024 season), the team has been taking on challenges competing in Division 1, the top division of the Japan Rugby League One. Working toward its goal to become the No. 1 team in Japan in three years’ time, the MIE Honda HEAT has been pursuing continuous initiatives to enhance its strength. In the meantime, in September of this year, the team announced its plan to relocate the base of activities to Utsunomiya City, Tochigi Prefecture sometime prior to the start of the 2026-2027 season, in order to offer more people the opportunity to see the team and get involved in its challenges toward its goal.Based on the company’s vision for its sports activities, Honda will continue to support various athletes who take on challenges toward the realization of their own dreams.Comment of Manabu Ozawa, Managing Executive Officer of Honda Motor Co., Ltd.“Honda sports teams, including the Honda Running Team, have inspired many people this year with their remarkable achievements, expanding their activities from Japan to the world. Our rugby team, getting ready for its second season with the new head coach Kieran Crowley, has built a team structure that reflects the strong will of Coach Crowley to achieve our goal to become the No. 1 team in Japan in three years’ time. We are committed to strengthening MIE Honda HEAT as a sports team that represents Honda corporate culture, demonstrating the collective strengths and teamwork of Honda. In two years, the team is relocating the base of its activities to Tochigi Prefecture, and will continue to strive for further growth. MIE Honda HEAT will continue to take on bold challenges and prove the power of believing in “The Power of Dreams” by playing matches that move people’s hearts. Thank you in advance for your continued support and cheers in the 2024-25 season.”Comment of Kieran Crowley, Head Coach of MIE Honda HEAT“The 2023-24 season, my first year as head coach, was a very difficult one, with only one win out of 16 games. Based on what I perceived as our challenges throughout the season, I brought in 14 new players during the off-season and also added new coaches. As a result of intense competition for positions within the team and the rigorous training experienced by all players, we have built a team with strong physical capability and the stamina to play 80 minutes at full strength. With a goal to be ranked sixth or above in the league, we will further improve our performance in the 2024-25 season, which will start soon. Please keep your expectations high for the great effort and performance of MIE Honda HEAT!”MIE Honda HEAT official website: https://www.honda-heat.jp/ (Japanese/English)Honda Sports Activity website:https://global.honda/jp/brand/sports/ (Japanese)JAPAN RUGBY LEAGUE ONE:https://league-one.jp/ (Japanese)https://league-one.jp/en/ (English) Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Dec 3, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has received a Minister of the Environment Award for Climate Action 2024 for development of its JHT-Y/JHT-YI series of large-capacity centrifugal chillers adopting the HFO-1234yf refrigerant with a low GWP(1). The award, sponsored by the Japanese Ministry of the Environment, was presented in the Technological Development and Commercialization category. An awards ceremony took place in Tokyo on December 2.The Awards CeremonyThe Minister of the Environment for Climate Action Award program was renewed in 2020 to reflect recent trends in climate change measures and succeeded the Environment Minister's Awards for Global Warming Prevention Activity, which had been held since 1998. The awards are given annually to individuals or groups having made noteworthy contributions to climate change mitigation (measures to curb greenhouse gas emissions) and accommodation to climate change (measures to avert or reduce impacts from climate change). This 2024 award is MHI Thermal Systems' third to date: in 2019, the Company received an Environment Minister's Award for its high-efficiency centrifugal chiller ETI-Z series that adopt a low-GWP refrigerant(2); and in 2021, the Company garnered the award for development and promotion of an air-to-water type heat pump using a low-GWP refrigerant(3).The constant-speed JHT-Y and inverter-equipped JHT-YI are new series for large-capacity centrifugal chillers launched in June 2022. Both models in the series adopt the HFO-1234yf refrigerant with extremely low environmental impact (GWP below 1) and the capacities ranging from 300 to 5,400 refrigeration tons (RT)(4). The JHT-Y and JHT-YI are the first centrifugal chillers with capacities up to 5,400 RT commercially offered in Japan with a low-GWP refrigerant. With a newly designed compressor, outstanding efficiency has been achieved: the constant-speed model to achieve a maximum rated COP(5) of 6.4, the inverter-equipped model achieves an IPLV(6) of 8.8 and a maximum part load COP of 24.9. A smaller compressor size, together with the optimized centrifugal chiller structure layout, also contributes to the effective use of the space, enabling smooth installation from existing equipment. The replacement of an existing equipment using a higher-GWP HFC (hydrofluorocarbon) refrigerant with the JHT-YI can reduce annual energy consumption and CO2emissions by approximately 65%(7), contributing significantly to mitigating environmental impacts. The JHT-Y and JHT-YI models are also adaptable to a wide range of applications: air-conditioning, heating, as well as low-temperature and heating processes in beverage plants, etc.The HFO-1234yf refrigerant, which is also used in car air-conditioners and vending machines, has a GWP of below 1 and ODP(8) of zero, and is categorized as non-Freon refrigerant according to Japan's Revised Fluorocarbons Recovery and Destruction Law(9). For these reasons, it is not subject to this Law that regulates the Fluorocarbons' emissions into the atmosphere, recovery, and destruction after usage. Concerning an equipment with higher-GWP HFC refrigerant including HFC-134a, which was widely used before the revised legislation took effect, it has been made compulsory to reduce in both their production and usage volumes as it has a significant impact on global warming. In 2025 and onward, it is scheduled that the regulations on the supply of equipment with higher-GWP refrigerants to the market will be tightened further in the Japanese market, therefore, currently the demands for the equipment with low-GWP refrigerants, ex. the JHT-Y/JHT-YI series, are increasing and earlier upgrading is required in the market.MHI Thermal Systems is Japan's leading manufacturer of centrifugal chillers, having delivered numerous units for district cooling/heating, factory air-conditioning, etc. Going forward, the Company will continue to focus on developing high-performance products using low-GWP refrigerants covering - together with the small and medium-capacity ETI-Z series - a capacity span of 150 to 5,400 RT, as its way of contributing to environmental protection on a global scale.(1) GWP: global warming potential. CO2 is assigned a GWP of 1. The lower the GWP factor, the less impact on the environment.(2) For further information, refer to the following press release: https://www.mhi.com/news/191203.html(3) For further information, refer to the following press release: https://www.mhi.com/news/21112502.html(4) Capacity above 2,700 RT requires two compressors (parallel type).(5) COP: coefficient of performance as calculated based on Japanese Industrial Standards (JIS). The higher the COP, the higher the level of energy savings.(6) IPLV: integrated part load value, an indicator of the efficiency of an air-conditioner during part load operation. The higher the IPLV, the higher the level of energy savings.(7) Compared with our previous model (20 years ago)(8) ODP: ozone depletion potential, a coefficient expressing the relative amount of degradation to the ozone layer compared to trichlorofluoromethane (CFC-11), a refrigerant previously in wide use which has a fixed ODP of 1.0. The lower the ODP, the lower the destructive impact on the ozone layer.(9) This revised law, which took effect on April 1, 2015, stipulates rules for the rational use and proper management of fluorocarbons.JHT-Y/JHT-YI SeriesAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, Dec 3, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has spun out blue carbon services company BLUABLE Ltd. from its entrepreneurship program Fujitsu Innovation Circuit (FIC.) The company, established as a startup in October 2024, is the first company to be successfully generated by the program.BLUABLE has secured funding from Spinout Capital Fund No.1, a Japanese venture capital fund for corporate spinouts, in November 2024. The funds will be used to validate the product-market fit of the products and services developed.BLUABLE aims to promote carbon neutrality and contribute to the sustainability of the marine environment by providing services related to blue carbon, i.e., carbon captured and stored in the world's ocean and coastal ecosystems.A significant amount of blue carbon is stored in seaweed, and a rise in seawater temperatures has caused a loss of seaweed beds and damage to seawater quality and conditions.BLUABLE produces kits to encourage seaweed bed growth. The kits are made from a material which seaweed can easily adhere to and no heavy equipment is needed to place the kits in the ocean, saving resources as compared to current cultivation methods. In addition, BLUABLE measures the blue carbon secured through utilization of its kits and uses the data to apply for J Blue Credits (1). Currently, BLUABLE is conducting field trials for seaweed bed cultivation at 16 undersea locations in Japan.The company plans to verify more advanced measuring techniques for blue carbon using IoT and AI.Fujitsu will provide its technology to BLUABLE, including its ocean digital twin (2), as it works toward preserving the world’s marine environment. In addition, through FIC, Fujitsu will continue contributing to a sustainable society by fostering talent and businesses that can take on the challenge of resolving societal issues.About Fujitsu Innovation Circuit (FIC)FIC, launched in November 2021 as part of Fujitsu Transformation, is a program to cultivate human resources with entrepreneurial skills and generate new businesses. FIC is comprised of the Ignition program that seeks to cultivate entrepreneurship, and the Challenge program that encourages employees to create new businesses. Over 2,500 Fujitsu employees around the world are participating in FIC.()) J Blue Credit :System of blue carbon credits issued and managed by the Japan Blue Economy (JBE) Association according to the results of an assessment and certification process implemented by an independent third-party committee.(2) Ocean digital twin :Technology that reproduces the marine environment with high precision in a digital space. Capable of collecting and modelling a wide variety of marine data.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has received an order from Shikoku Electric Power Co. Inc. (Shikoku) to supply 24 MOX(1) fuel assemblies for Unit 3 of the Ikata Nuclear Power Station, subsequent to the order received in October from Kyushu Electric Power Co. Inc. for Unit 3 of the Genkai Nuclear Power Station. Under this contract, MHI will perform design of MOX fuel, and have components such as cladding tubes manufactured by Mitsubishi Nuclear Fuel Co., Ltd. (MHI Group) provided to Orano, who will fabricate MOX fuel assemblies at its MELOX plant in France.MHI has previously supplied 57 MOX fuel assemblies to Japanese utilities, and will supply high-quality MOX fuel by leveraging its past experience and technical capability. MOX fuel will enable Shikoku to utilize plutonium extracted by reprocessing spent fuel, and MHI will contribute to steady promotion of Shikoku's "Plu-Thermal" plan(2) through the supply of MOX fuel.(1) MOX (Mixed Oxide Fuel) is nuclear fuel made of plutonium extracted by reprocessing of spent fuel, and uranium.(2) The "Plu-Thermal" plan is to utilize MOX fuel in light water reactors.Tags: nuclear power generation,MOX fuel assemblyAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Honda Research Institute Japan Co., Ltd. (HRI-JP), a Honda R&D subsidiary responsible for the research of cutting-edge technologies, has officially introduced its AI-powered social robot named “Haru” at the Virgen del Rocío University Hospital (HUVR) in Seville, Spain, to enhance the well-being of children while in the hospital.At the Annual Gala against Childhood Cancer, held on November 28 local time, at Casino de la Exposicion in Seville, Spain, the HUVR introduced Haru as one of the projects HUVR is implementing to improve the lives of children with cancer, who are in the hospital for long-term treatment.AI-powered social robot, HaruHRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility.Honda Research Institute Japan Co., Ltd. (HRI-JP), a Honda R&D subsidiary responsible for the research of cutting-edge technologies, has officially introduced its AI-powered social robot named “Haru” at the Virgen del Rocío University Hospital (HUVR) in Seville, Spain, to enhance the well-being of children while in the hospital.At the Annual Gala against Childhood Cancer, held on November 28 local time, at Casino de la Exposicion in Seville, Spain, the HUVR introduced Haru as one of the projects HUVR is implementing to improve the lives of children with cancer, who are in the hospital for long-term treatment.AI-powered social robot, HaruHRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility.HRI-JP has been developing Haru, an AI-powered social robot, as a “tangible AI system” striving to realize a society where robots coexist as partners of people and to facilitate communications that create connections among people. Haru was designed to be a social robot that makes people smile through expressive communications and forms empathetic relationships with people. As a compact desk-top robot with a total height of 30cm (12 inches), Haru can be placed on a table to engage in communications with people.Haru obtains biometric information of the user, such as facial expressions and voice tones, through its built-in camera and microphones, then analyzes the information obtained to understand the user’s current state, and interacts with each user in accordance with the result of analysis, using empathetic expressions and emotionally supportive responses. Moreover, Haru can also be linked to a wristwatch-type wearable sensor worn by the user and analyze the user’s conditions in greater detail.Furthermore, as a robot, Haru does not have any human attributes such as gender, race or nationality, and is always capable of communicating from a neutral perspective, enabling Haru to effectively facilitate communication beyond generational and cultural differences, especially in group communication.HUVR had been conducting a demonstration experiment using Haru in the pediatric oncology ward of the hospital since 2021 for the purpose of enhancing both the clinical and emotional care of young patients. Since the results of the experiment have confirmed a certain level of positive effects on children with cancer, the official decision was made to advance the project with full-fledged utilization of Haru, introducing 10 units to be used in various situations in the children’s daily lives in the pediatric oncology unit.Key results of the demonstration experiment at the HUVR1. Assisting emotional and cognitive assessmentsHaru has been assisting the hospital’s neuropsychologists in conducting emotional and cognitive assessments. Using AI technology, Haru communicates with children; analyzes their biometric information, such as facial expressions and voice tones, obtained through its built-in cameras and microphones; and assist neuropsychologists in conducting emotional and cognitive assessments.Due to the amount of time the assessment takes, there is a limit to the number of assessments the neuropsychologists can conduct each year: the number had been limited to 510 per year including follow-up consultations until now. With the introduction of Haru, the number of assessments the hospital can conduct each year is expected to increase to as many as 4,500.2. Assisting rehabilitation activitiesHaru has been supporting intellectual and physical rehabilitation programs provided to young patients at the hospital. Haru learns the rehabilitation programs and can guide the children through the process while engaging them in conversation. The demonstration experiment showed that 95% of children were more actively engaged in rehabilitation while receiving guidance from Haru, compared to conventional human guides.3. Serving as a companion in playrooms and hospital roomsYoung patients who undergo long-term hospital stays for treatment spend a lot of time alone in their rooms. By communicating with the children, Haru can offer entertainment and cognitive stimulation, and help to soothe their feeling of loneliness, contributing to the enhancement of emotional care the hospital provides.4. Offering educational supportHaru connects the hospital rooms of the children who have not been able to attend school with the classrooms of their schools online, and facilitates the communication as an intermediary. This provides children at the hospital with opportunity to receive education together with children in the classroom and to interact with each other among children.Comments by the Virgen del Rocío University Hospital in Seville (HUVR)“We have been conducting joint research with HRI-JP for several years now, and gained wonderful results. We have identified that Haru holds great potential in bringing happiness to children. Typically, technologies used in hospitals focus on medical treatments or physical well-being. However, Haru has positive psychological effect of lightening the mood of our young patients and also contributes to the well-being of the hospital as a whole. The support that Haru provides, enabling children under hospital care to feel more happiness and connection with others, is unique only to Haru and offers valuable benefits not found in traditional medical care. We believe that Haru is a groundbreaking presence that creates an environment where young patients can enjoy their time here at our hospital.”Comments by Satoshi Shigemi, Honda Research Institute Japan Co., Ltd. (HRI-JP)“Based on the founding spirit of Honda, ‘using our technology to help people’ and ‘understanding people is the very essence of Honda monozukuri (art of making things),’ Honda Research Institute has been conducting research into cutting-edge technologies which have the potential to enhance positive psychological effects of people and the overall well-being of society. We are delighted by the result of our joint research with Virgen del Rocío University Hospital that shows Haru has been able to be a companion to the children at the hospital, lifting up their spirits, and bringing smiles to their faces. Moving forward, we will continue our efforts to further advance Haru as a robot which can co-exist with people 24/7 and be more helpful to young patients as well as all hospital staff to contribute to the well-being of the hospital a whole.”About Honda Research Institute (HRI)HRI was established in 2003 as a research operation which will go beyond the framework of the traditional business domain of the Honda Group and take on challenges to address issues facing humanity. Each of three HRI operations, located in Japan, the United States, and Germany, is engaged in “frontier research” with a focus on next-generation AI, including the exploration of new technologies such as quantum technology. By using Pasteur's Quadrant approach to research, which calls for the simultaneous pursuit of principles, or science, and real-world applications, HRI is striving to quickly give shape to new technologies and ideas, and create new value that can be useful to society. The research outcomes generated by HRI will lead toward the development of future Honda technologies in a wide range of technology fields, including but not limited to the areas of safety, the environment and next-generation mobility. Copyright 2024 JCN Newswire via SeaPRwire.com.

KARIYA, JAPAN, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - DENSO Sales Middle East & North Africa (DSMN), a group company of DENSO Corporation, will participate in “Automechanika Dubai 2024,” held at the Dubai World Trade Centre from December 10 to 12, 2024.Established in 2010 in Dubai, DSMN serves the Middle East and North Africa regions by offering aftermarket products and services. In these regions, motorization is advancing, and vehicles tend to have longer operational lifespans. DSMN strives to provide customers and users with peace of mind and trust through high-quality products and services, contributing to the realization of a sustainable mobility society.Automechanika Dubai is the largest automotive aftermarket trade show in the Middle East and Africa. This year, over 2,200 exhibitors are expected to participate. Many visitors are businesses seeking to establish partnerships with exhibitors, and attendance is anticipated to exceed last year’s 52,469 visitors from 161 countries. The event offers an excellent opportunity to expand business possibilities, not only in the Middle East and Africa but also in regions such as West Asia and Central Asia.Through this exhibition, DSMN aims to showcase aftermarket solutions and explore opportunities for advanced technology-based products and services. Additionally, DSMN will deepen interactions with customers and partner companies, identifying new needs and pursuing tailored solutions to address regional challenges.Booth ImageDSMN Website: https://denso.ae/Please see here for more details on DSMN’s booth: https://denso.ae/events/join-us-at-automechanika-dubai-2024-celebrating-75-years-of-innovation Copyright 2024 JCN Newswire via SeaPRwire.com.

KAWASAKI, Japan, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced that it has signed a three-year global strategic collaboration agreement (SCA) with Amazon Web Services (AWS) (1). This collaboration, officially concluded on November 29, expands the existing agreements in the mobility, finance, and retail sectors to a broader range of industries .Through this collaboration, Fujitsu will combine its expertise in systems integration and its Fujitsu Uvance offering to solve societal issues with AWS’s cloud services and cloud-native architecture to accelerate customers' digital transformation (DX) and address business challenges.Additionally, with AWS’s skills training, Fujitsu aims to strengthen its delivery system by increasing the number of Fujitsu engineers who have AWS certifications from approximately 7,000 to 12,000 over the next three years and double the number of customer deals to over 800 compared to the past 3-year SCA period.BackgroundWith the target year of 2030 for achieving the United Nations Sustainable Development Goals (SDGs) approaching, Fujitsu is promoting Fujitsu Uvance, its business model that aims to increase business growth and solve societal issues.Fujitsu Uvance leverages Fujitsu's extensive technology and industry expertise to seamlessly integrate fragmented processes and data, with the aim of creating new solutions and insights for customers. To achieve this, it is crucial to move away from legacy systems and strategically utilize cloud computing with partners. By expanding strategic collaboration with AWS, the world’s most comprehensive and broadly adopted cloud, and creating a combined solution that address customers business challenges and opportunities, Fujitsu will drive digital transformation across industries.Overview of the Initiatives1. Strengthening Fujitsu’s AWS cloud migration support servicesIn addition to having customers core systems run on their mainframes and UNIX servers, which was a strategic target of the legacy modernization collaboration announced in March 2024, the two companies will strengthen migration support services for broader on-premise systems to move onto AWS. Fujitsu will provide a comprehensive set of cloud-native system integration and operation support services through Fujitsu Cloud Transformation Service and Fujitsu Cloud Managed Service (2), with technical support from AWS.2. Enhancing added value through the service integration of Fujitsu Uvance offerings and AWSFujitsu aims to enhance added value and expand the global provision of Fujitsu Uvance offerings focusing on the two pillars of Trusted Society for a prosperous and sustainable society and Digital Shifts to support customers' data-driven strategies. As part of this effort, Fujitsu has started linking the Digital Shifts offering with its Fujitsu Kozuchi AI service and Amazon Bedrock, AWS's generative AI service. For example, Fujitsu Data Intelligence Premium, an operation platform that utilizes data and AI, analyzes production line data from factories, uses AI to detect risk signs and propose countermeasures based on past cases, and converts past inspection reports into reusable structured data to visualize and share accumulated know-how in facility maintenance work within organizations. By combining business knowledge cultivated over many years with the latest technologies such as generative AI, Fujitsu will help customers improve the efficiency and the uptime of their production processes. Demonstrations of these use cases will be showcased at the Fujitsu booth during AWS re:Invent 2024 starting today in Las Vegas, US.(3)3. Reinforcing Fujitsu’s system development and delivery capabilities by increasing the number of AWS certification holdersFujitsu aims to increase the number of Fujitsu engineers who hold AWS certifications from approximately 7,000 to 12,000 over the next three years, through AWS skills training. By increasing the number of professionals who have a deep understanding of AWS cloud services, Fujitsu will accelerate the delivery of systems that realize customers' DX, doubling the number of customer deals to over 800 compared to past 3-year SCA period.Role of Fujitsu and AWS- FujitsuLeverage its customer base and system development expertise in various industries to reach enterprise and mid-market customers.Through offerings such as legacy system modernization, cloud migration and operational support, and Fujitsu Uvance, Fujitsu will support customers' DX.- AWSAWS will strengthen its technical support for Fujitsu with its solution architects and provide advisories on the use of latest AWS services such as generative AI and cloud-native architectures for diverse use cases. AWS will also provide development environments to review latest AWS services, while also offering funds for joint sales and marketing, and AWS training and certifications for Fujitsu engineers.Yoshinami Takahashi, Vice President and COO for Uvance, Fujitsu Limited comments:“We are pleased to have concluded this global strategic collaboration with AWS. By extending our strategic collaboration to a broader range of industries, we will contribute to the digital transformation of customers across industries through legacy modernization, cloud lift and shift, and the utilization of technology and data offerings from Fujitsu Uvance together with AWS."Jaime Vallés, Vice President, Asia Pacific and Japan, Amazon Web Services comments:"Since 2012, AWS and Fujitsu have supported the digital transformation of customers in the mobility, finance, and retail sectors in Japan and worldwide. Today, we are delighted to expand our strategic collaboration with Fujitsu. Together we will broaden our Digital Transformation Experience to enable a wider range of industries and leverage our shared culture of innovation to jointly address some of the world’s biggest challenges."(1) Amazon Web Services: Headquartered in Seattle, Washington, USA, CEO Matt Garman. The collaboration was concluded with Amazon Web Services Japan GK (Head Office: Shinagawa-ku, Tokyo; President: Akihiko Shirahata).(2) Fujitsu Cloud Transformation Service and Fujitsu Cloud Managed Service: Based on Fujitsu's system design, construction, and operation know-how cultivated mainly in the enterprise domain, these services realize standardization and automation of architecture patterns, ensuring high quality while achieving cost-optimized and rapid delivery. Fujitsu adopts the "AWS Well-Architected Framework" in its delivery services, which is optimized for AWS, and has obtained the "AWS Managed Service Provider (MSP)" certification, proving the soundness and high technical capability of its AWS business.(3) AWS re:Invent: AWS’s annual global conference that starts from December 2, 2024 in Las Vegas. For more information on AWS re:Invent, please visit: https://reinvent.awsevents.com/About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.

TOKYO, Dec 2, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has received an order from Taiwan High Speed Rail Corporation to install new equipment and modify existing equipment for the expansion of the existing maintenance shop at Taiwan High Speed Rail's (THSR) Zuoying depot in southern Taiwan. MHI will design, supply and install trackwork, overhead catenary system, power supply system, and signaling system.THSR plays a key role in Taiwan's transportation infrastructure. Its annual ridership has increased from around 15 million passengers during its inaugural year in 2007, to nearly 73 million in 2023, with the cumulative ridership to date now exceeding 800 million. To better serve this increasing demand, THSR is boosting its capacity by adding 12-car train sets and expanding the associated inspection and maintenance facilities which MHI will undertake. These upgrades will enable an increase in train car operations, which will further enhance transportation convenience across Taiwan and support its economic growth.The THSR project was initially awarded to a consortium of seven Japanese companies, including MHI, in 2000. Operations were inaugurated in January 2007. MHI's involvement continued with the Nangang Extension Project(Note) and subsequent system upgrade work, and the latest contract was awarded to MHI in recognition of these and other ongoing contributions to THSR's development.Going forward, MHI will continue contributing to the THSR's development through its expertise in transportation systems and project management capabilities, further enhancing Taiwan's transportation infrastructure.For details concerning the Nangang Extension Project, refer to the following news release: www.mhi.com/news/130624en.htmlAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.